In the first half of the 2025/26 financial year, Ypsomed completed its transformation. Following the sale of the Diabetes Care business, we are now concentrating on our core competency: innovative self-injection systems. We offer pharmaceutical and biotech companies worldwide tailor-made solutions for self-treatment – solutions based on the most comprehensive and innovative platform portfolio in our industry.